TrialArteriosclerosis, thrombosis, and vascular biology2019

Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Christina U Lorentz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.